This study investigated the clinical course of arrhythmogenic right ventricular cardiomyopathy (ARVC) patients and in particular evaluated the contribution of radiofrequency catheter ablation (RFCA) and an implantable cardioverter-defibrillator (ICD) to the treatment of ARVC.
A rrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare myocardial disorder characterized by fibro-fatty replacement of the right ventricular myocardium. 1) It is now well known that ARVC is a cause of sudden cardiac death (SCD) in young people and/ or athletes due to ventricular tachycardia (VT). 2) One of the main goals in the treatment of ARVC is suppression of the VT that results in SCD. Treatment of ARVC is divided into pharmacologic and nonpharmacologic therapies.
The success of drug therapy for control of VT recurrence in ARVC is difficult to evaluate, but the effectiveness of sotalol to suppress the VT has been reported. 3) Various nonpharmacologic approaches to suppress this VT have been evaluated. Ventriculotomy was performed in the early days, but it resulted in high mortality rates. 4) Although acute success rates of 60-90% have been reported with radiofrequency catheter ablation (RFCA), VT recurrence is common and may lead to SCD. 5) Several studies have reported that implantable cardioverter-defibrillator (ICD) therapy prevents SCD by termination of VT. [6] [7] [8] Pharmacologic therapies using sotalol or amiodarone alone or in combination with beta-blockers are considered the first choice of treatment for patients with ARVC. 5) Thus, implantation of an ICD is recommended in patients with aborted SCD or inducible VT by electrophysiologic study (EPS). RFCA is considered to decrease appropriate intervention of the ICD by partial prevention of VT and to improve quality of life.
The prevalence of ARVC varies widely according to the study population, and the geographic distribution of the disease is controversial. 9) Hulot, et al reported an annual mortality rate of 2.3% and mean age at death of 54 ± 19 years as the natural history of ARVC in France. 10) Other investigators reported the prognosis of ARVC in Italy, the United States, and Spain. However, little is known about the prognosis of Japanese patients with ARVC undergoing ICD implantation or other treatments. It is reasonable to assume that the severity and clinical course of this disease may be different depending on race and geographic region because a variety of genetic factors has been reported. Thus, the aim of this study was to investigate the clinical course of ARVC patients and to evaluate the efficacy of RFCA and ICD in combination with pharmacologic treatment.
Methods
Patients: Patients who were diagnosed as having ARVC at 10 hospitals in the eastern part of the main island of Japan were included in this study. Data were extracted from the medical records of each patient. These included demographic data, clinical data (family history of ARVC or heart disease, initial presentation of the disease, age at onset, physical examination), electrocardiograms (ECG), signalaveraged ECG, holter monitoring, echocardiograms, coronary angiography, left and right ventriculography, endomyocardial biopsy and treatment, and major clinical events.
Thirty-five Japanese patients (26 males and 9 females) were diagnosed as having ARVC on the basis of the standardized criteria for classification of cardiomyopathies recommended by the European Society of Cardiology Working Group on Myocardial and Pericardial Disease and the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology (McKenna's criteria).
11) This study protocol was approved by the Ethical Review Board of the Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University. Group definition: Thirty-five patients were divided into three groups according to the diagnosis at the first hospital visit: CHF group (n = 3), VT group (n = 30), and premature ventricular conductions (PVC) group (n = 2). The VT group was further classified according to the initial treatment for VT: RFCA group (n = 14), ICD group (n = 7), ICD plus RFCA group (n = 5), and medication follow-up group (Med group, n = 4). The RFCA group included 8 patients who underwent RFCA therapy without ICD implantation and 6 patients who underwent RFCA therapy before ICD implantation. All patients in the ICD group underwent ICD therapy and received medication but not RFCA treatment. All patients in the ICD plus RFCA group underwent ICD implantation and RFCA therapy at their initial assessment ( Figure 1 ). Two patients in the PVC group were treated with RFCA therapy, which eliminated their PVCs. They took no antiarrhythmic drugs, and no PVCs or VT have been documented during the follow-up period. Thus, we compared the CHF group and VT group statistically. Statistical methods: Data are expressed as the mean ± SD for statistical analysis. Student's t-test was used for comparison of age, sex, ECG parameters, duration of followup, existence of ventricular wall motion abnormality, and frequency of hospital admission between the VT and CHF groups. Survival rates were estimated by the Kaplan-Meier method and compared by the log-rank test. A P value less than 0.05 was considered statistically significant. All statistical analyses were performed with SPSS statistical software (version 11.0, SPSS Inc., Chicago, Illinois).
Results

Patient characteristics:
The patient characteristics are described in Tables I and II . The male/female ratio was 2.9 : 1. Mean age at onset was 45.6 ± 15.6 years (range, 15 to 79 years). Average follow-up period from onset was 54.5 ± 48.2 months, and the follow-up period ranged from 1 to 183 months.
Initial symptoms at the onset of ARVC were palpitations (21 patients), syncope (5 patients), dyspnea (3 patients), dizziness (1 patient), shortness of breath (1 patient), and chest pain (1 patient). There were 3 asymptomatic patients at the time of first presentation. Clinical diagnoses at onset were ventricular tachycardia (30 patients, VT group), congestive heart failure (3 patients, CHF group) and PVCs (2 patients) ( Table III) . One of 35 patients had evidence of a family history of ARVC. Eleven patients had family histories of heart disease: 3 sudden deaths, 3 arrhythmias, 1 congenital heart disease, 1 angina pectoris, and 3 other heart diseases whose details were not described in the medical records. Only 2 patients had a normal 12-lead ECG recording. T-wave inversion in the right precordial leads (V2 and V3) in the absence of right bundle-branch block was recorded in 9 patients, and an Epsilon-wave was recorded in 28 patients. An abnormal signal-averaged ECG was present in 25 of 29 patients. In 22 of the 29 patients, VT was induced by right ventricular myocardial stimulation during EPS. Sixteen patients underwent endomyocardial biopsy, and fibro-fatty replacement was observed in the right ventricular wall in 12 patients.
Twenty-six patients in the VT group were treated with antiarrhythmic drugs including beta-blockers in 16 patients, amiodarone (mean, 164 mg, range, 100 -200 mg) in 14, sotalol (mean, 120 mg, range, 80 -160 mg) in 2, procainamide in 2, pirmenol in 2, aprindine in 1, disopyramide in 1, flecainide in 1, cibenzoline in 1, and verapamil in 1, used alone or in combination. The 4 remaining patients did not receive any medication after RFCA because VT could not be induced by EPS performed several months after RFCA Outcome   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35   15  16  19  21  25  27  29  32  36  38  40  41  41  43  45  45  46  47  48  49  50  51  53  55  56  56  57  58  59  60  61  62  66  70 79 19  16  146  10  38  65  36  183  151  97  12  14  133  48  92  11  5  123  31  102  82  29  66  54  14  17  86  5  34  59  52  1  49  5 CLINICAL COURSE OF ARVC WITH ICD OR RFCA in 3 of the patients and because the other patient wanted to get pregnant. Four patients out of 35 died of progressive heart failure, and one patient died of VT/VF recurrence ( Figure 1 ). VT group: Palpitations and syncope were the most common presenting symptoms in the VT/VF group. Fifteen of the 30 patients were transferred to the emergency room with VT as the manifestation of the disease and received treatment to terminate the VT by direct current cardioversion, automated external defibrillator, or antiarrhythmic drug infusion. Mean age at onset in this group was 44.5 ± 14.8 years. Twenty-three of 30 patients were male. The clinical course of patients included in the VT group is described in Figure 1 . Five patients underwent RFCA plus ICD therapy at the first assessment. One of these 5 patients had at least one episode of VT recurrence after the RFCA and ICD therapy. Fourteen patients received RFCA therapy without ICD therapy for VT at first assessment (RFCA group). Mean duration from first visiting our hospitals to RFCA was 15.2 ± 44.4 months (range, 1 to 168 months) and the median was 2.0 months. One patient visited a hospital in August 1991 and received RFCA therapy in August 2005. During the follow-up period VTs recurred in 9 of these patients. One patient died at 18 years of age from VT/VF that occurred during exercise 16 months after RFCA therapy. An ICD was implanted in 6 patients in the RFCA group after recurrence of VT or a second or third session of RFCA therapy. The average period from first RFCA therapy to ICD implantation was 43.0 ± 25.5 months. Second RFCA therapy was performed in 6 patients, and third RFCA therapy was performed in 2 patients. Five of the 6 patients who underwent a second or third session of RFCA therapy also underwent ICD implantation.
All 19 patients in the VT group underwent RFCA therapy for VT, and VT recurred in 10 (52.6%) of these 19 patients. The mean period from RFCA therapy to VT recurrence was 14.0 ± 20.1 months (range, 1 to 66 months). Average duration of follow-up in the 9 patients free from VT recurrence was 57.6 ± 31.0 months (range, 5 to 92 months). Among the 10 patients with VT recurrence, 1 received a beta-blocker only, 2 received a beta-blocker with another antiarrhythmic drug, 1 received a beta-blocker with amiodarone, and 3 received amiodarone with another antiarrhythmic drug. In the 9 patients without recurrence of VT, 2 received a beta-blocker only, 2 received a betablocker with amiodarone, and 1 received amiodarone alone. There was no significant difference in medications between the two groups. Seven patients who did not undergo RFCA therapy were implanted with ICD (ICD group), and one died of progressive heart failure without VT recurrence 32 months after implantation. In total, 18 of the 30 VT group patients underwent ICD implantation. At least one episode of VT recurred in 6 of these 18 patients (33.3%), and they received appropriate ICD intervention.
The 4 patients not undergoing RFCA nor ICD therapy for VT were categorized into the Med group. These patients received beta-blocker alone, beta-blocker with aprindine, beta-blocker with disopyramide, or amiodarone alone.
Mean follow-up duration in this group was 72.6 ± 59.9 months. Cardiac events including SCD, hospitalization, or visiting an emergency room due to VT or CHF did not occur in the follow-up period.
Comparison of duration from the initial therapy to recurrence of VT between the RFCA group and the ICD group plus the Med group is shown in Figure 2 . Duration without VT recurrence and rate of VT recurrence after ICD or RFCA therapy were not significantly different. Mean duration from RFCA/ICD to VT recurrence was 12.7 ± 20.1 months in the RFCA group and 5.3 ± 4.0 months in the ICD group (P = 0.45). In this study, one patient died of VT/VF in the RFCA group, and one patient died of CHF in the ICD group. ICD therapy showed no improvement in mortality over that of RFCA in this study. However, ICD therapy did reduce the episodes of hospitalization compared with RFCA therapy. The average number of episodes of hospitalization was 0.1 ± 0.4 (range, 0 to 1 episodes) in the ICD group and 1.7 ± 2.2 (range, 0 to 7 episodes) in the RFCA group ( Figure  3 ). CHF group: The symptom at the onset of ARVC in the 3 patients comprising the CHF group was dyspnea with increasing cardiothoracic ratio on chest X-ray film. RV dilatation with hypokinesis was observed in all patients by echocardiography. Two patients had diffuse severe hypokinesis of the left ventricular wall and died of progressive heart failure. One patient recovered from CHF with conservative therapy and showed good LV function by left ventricular angiography (left ventricular ejection fraction (LVEF) = 72%), but 5 months later, he was rehospitalized and died of CHF. All patients in this group had at least one episode of nonsustained VT without hemodynamic collapse. None were treated with antiarrhythmic drugs. Mean age at onset in the CHF group was 66.0 ± 4.0 years. Duration of follow-up was 18.3 ± 26.6 months. Autopsy diagnosis was established in all CHF group patients. Fibro-fatty replacement was observed in both the right ventricular and left ventricular walls in all patients. Pathologic diagnosis Parameters between the CHF and VT groups are compared in Table II . Mean age at onset in the CHF group was significantly higher than that in the VT group (66.0 ± 4.0 versus 44.5 ± 14.8 years, P = 0.02). The CHF group showed significantly higher mortality compared to the VT group (P < 0.001) ( Figure 5 ). There were no significant differences according to sex, ECG abnormality (complete or incomplete right bundle-branch block, Epsilon-wave, Twave inversion in the right precordial leads in the absence of right bundle-branch block), and RV dilatation between the two groups at initial evaluation.
Discussion
In this study, we found that ARVC patients with CHF onset had a poor prognosis, and recurrence of VT was greater than 50% in patients treated with RFCA treatment. This recurrence rate was not less than that in patients without RFCA treatment. ICD therapy did not improve mortality in comparison with RFCA or medical treatment but did significantly reduce rehospitalization compared with RFCA therapy.
One of the main purposes of therapy for ARVC patients is prevention of SCD because ARVC is a major cause of ventricular arrhythmias and sudden death in young people and athletes. ICD therapy is increasingly used for secondary and also primary prevention of sudden death in patients with ARVC and improves their long-term prognosis and survival. 5, 6) Another report found that patients with ARVC treated with an ICD have an excellent prognosis, 12) and Hodgkinson, et al reported that the 5-year mortality rate of male ARVC patients with ICD therapy was 0% compared to 28% in control patients. 13) Mild hypokinesis of left ventricular wall motion has been reported at onset of ARVC, but CHF as a manifestation of ARVC is rare. 1, 14) However, a case of late-onset ARVC manifesting with CHF at age > 60 has been reported. 15) Other investigators reported an increase in left ventricular end-diastolic volume with normal ejection fraction in adult patients with ARVC in comparison to young patients with the disease.
16) Basso, et al reported the prognosis of 30 patients with ARVC: 24 died from SCD and 3 from CHF, and 3 patients underwent cardiac transplantation due to CHF. They also indicated that the mean age of CHF manifestation was older than that in other patients without CHF. 17) Hulot, et al reported that progressive heart failure as a cause of death in ARVC patients was twice as frequent as SCD. 10) In the present study, 4 patients died of CHF and one died of ventricular arrhythmia. Age at the time of death in all 4 patients who died of CHF was > 60 years (average age, 67.8 ± 6.6 years). Roguin also reported on a patient with ARVC who had end-stage disease with severe biventricular dysfunction and cavity dilation after ICD implantation and who subsequently underwent heart transplantation. 18) One of our patients also died of progressive heart failure 32 months after ICD implantation without VT recurrence. The diagnosis was established in all CHF group patients at autopsy. The existence of fibro-fatty replacement in both ventricles revealed that CHF progressed from right ventricular failure to biventricular failure leading to death by progressive heart failure.
From these data we conclude that prevention of SCD with ICD therapy improves survival rates of patients with early-to mid-stage ARVC, but CHF becomes the main clinical problem in the final stage of ARVC. Some of our patients also showed insidious progression of right ventricular disease without manifesting electrical disturbances leading to left ventricular involvement. In these cases, left ventricular failure can be the initial clinical symptom. The treatment of heart failure was difficult in all of these patients, and they died rapidly of progressive CHF. Elderly ARVC patients presenting with CHF clearly have a very poor prognosis.
The published results of catheter ablation in ARVC show that acute success can be achieved in 60-90% of patients. However, during long-term follow-up of 3-5 years, recurrence rates of as high as 50-70% were reported. 5, 6) The pros and cons of the efficacy of RFCA with electroanatomic mapping to suppress VT were also reported. [19] [20] [21] We used electroanatomic mapping techniques in one patient to suppress frequent VT recurrence after RFCA and ICD therapies. We consider the efficacy of the electroanatomic mapping technique to be controversial. In the present report, we obtained a 68.4% acute success rate with RFCA, whereas the VT recurrence rate was 52.6% during the observation period. These results indicate that RFCA may be effective to suppress VT occurrence, but it may not effectively prevent VT recurrence over the long term.
Although there has been no prospective randomized trial comparing ICD implantation with RFCA in patients with ARVC, ICD implantation is considered the most appropriate therapeutic option to prevent life-threatening VT recurrences and sudden death. 6, 7) It was reported that 66% of the ARVC patients undergoing ICD implantation for prevention of VT had at least one appropriate intervention during a 4.4 ± 2.9-year follow-up period. 22) We found that RFCA treatment was comparable to that of ICD implantation to prevent cardiovascular death. However, ICD treatment statistically reduced the frequency of hospitalization in comparison to that with RFCA. We speculate that patients with recurrent VT after RFCA are more likely to be hospitalized in Japan than are patients with VT terminated by ICD. We also speculate that Japanese cardiologists tend to perform RFCA to prevent VT in ARVC patients because appropriate clinical data on the long-term effect of RFCA therapy for ARVC are not yet available. The results of the present study suggest that the effects of ICD implantation in improving the ARVC patient's quality of life are superior to those of RFCA, at least in regard to rehospitalization. Study limitations: This study has some limitations. First, it was a retrospective and not a case controlled study. Second, our data did not include ARVC patients manifesting with sudden cardiac death. Third, the majority of the study population admitted to our hospitals for treatment of ventricular arrhythmias included several patients introduced from other hospitals due to recurrence of VT after RFCA therapy. Thus, there may be patient selection bias, and the patients in this study may not adequately represent the general ARVC population in Japan. Fourth, the number of patients is relatively small, and only two patients died of ARVC in the VT group. Fifth, the observation period may have been too short to adequately address the natural clinical course of this disease. Furthermore, because remarkable progress has been made recently in the pharmacologic prevention of ventricular arrhythmia, the effects of these new agents should have been evaluated. Conclusion: In the present study, a minor but significant population of patients presented with CHF as their initial manifestation of ARVC. The prognosis of these patients may be very poor. Recurrence of VT was relatively higher in the patients treated with RFCA therapy, and this rate was not reduced by additional RFCA therapy. ICD therapy did not improve the mortality rate in comparison with RFCA in our patients, but it did significantly reduce the number of hospitalizations in comparison with RFCA therapy.
